DAFTAR PUSTAKA

1. Berrih Aknin, Frenkian Cuvelier, Eymard B. Diagnostic and clinical classification of autoimmune myasthenia gravis. *J. Autoimmun.* 48–49, 143–148 (2014).
2. Wihadhi J. C. Strategi coping penderita myasthenia gravis. 62–84 (2016).
3. Klehmet J. Quantitative grip force assessment of muscular weakness in chronic inflammatory demyelinating polyneuropathy. *BMC Neurol.* 19, 1–9 (2019).
4. Benditt JO, Boitano LJ. Pulmonary issues in patients with chronic neuromuscular disease. Am J Respir Crit Care Med. 2013;187:1046–55.
5. Disorders, M. N. Written and compiled by the APCP Neuromuscular Committee Guidance for Paediatric Physiotherapists Managing Neuromuscular Disorders. (2017).
6. Richman DP. The future of research in myasthenia. *JAMA Neurol.* 72, 812–814 (2015).
7. Finnis MF, Jayawant S. Juvenile myasthenia gravis: A paediatric perspective. *Autoimmune Dis.* 1, (2011).
8. Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis: A review. *Autoimmunity* 48, 362–368 (2015).
9. Donohoe KM. Nursing care of the patient with myasthenia gravis. *Neurol. Clin.* 12, 369–385 (2004).
10. Gilhus NE, Owe JF, Hoff JM, Romi F, Skele GO, Aarli JA. Myasthenia gravis: a review of available treatment approaches. *Autoimmune Diseases*. 10:1–6 (2010).
11. Verschuuren, Maartje GH, Melzer N, Ruck T. Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. *Autoimmun. Rev.* 12, 918–923 (2013).
12. Parr JR, Jayawant S. Childhood myasthenia: Clinical subtypes and practical management. *Dev. Med. Child Neurol.* 49, 629–635 (2007).
13. Li J, Lisak RP. Pathophysiology of myasthenia gravis. *Gen. Thorac. Surg. Seventh Ed.* 2–2, 6035–6046 (2011).
14. Husaini Y, Sadjaja, Husaini MA. KMS remaja, relevansinya dengan pemantauan tumbuh kembang dalam upaya meningkatkan gizi dan kesehatan. *Ejournal.Litbang.Depkes* 9, 68–78 (2014).
15. Sanders DB, Wolfe GI, Narayanaswami P. Author response: International consensus guidance for management of myasthenia gravis: Executive summary. *Neurology* 88, 505–506 (2017).
16. Kumar V, Kaminski HJ. Treatment of myasthenia gravis. *Curr. Neurol. Neurosci. Rep.* 11, 89–96 (2011).

17. Wendell LC, Levine JM. Myasthenic Crisis. *The Neurohospitalist* 1, 16–22 (2011).
18. Varni JW, Sherman SA, Burwinkl TM, Dickinson PE, Dixon P. The PedsQL^{TM} Family Impact Module: Preliminary reliability and validity. *Health Qual. Life Outcomes* 2, 1–6 (2004).
19. Barnett C, Herbelin L, Dimachkie MM, Barohn RJ. Measuring Clinical Treatment Response in Myasthenia Gravis. *Neurol. Clin.* 36, 339–353 (2018).
20. Vander Pluym. Clinical characteristics of pediatric myasthenia: A surveillance study. *Pediatrics* 132, 939–944 (2013).
21. Harkitasari S. Diagnosis dan terapi miastenia gravis pada anak. *Cermin Dunia Kedokt.* 42, 181–185 (2015).
22. Syahrul S, Mutiawati E., Astini N, Fajri N, Suherman S. Clinical Characteristic Myasthenia Gravis among Indonesians. *Budapest Int. Res. Exact Sci. J.* 2, 257–263 (2020).
23. Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: Still a relevant outcome measure. *Muscle and Nerve* 44, 727–731 (2011).
24. Bhagat H, Grover V, Jangra K. What is optimal in patients with myasthenic crisis: Invasive or non-invasive ventilation? *J. Neuroanaesth. Crit. Care* 01, 116–120 (2014).
25. Setiawan M. Tinjauan Pustaka Gangguan Respirasi pada Penyakit Saraf. 40, 589–593 (2013).
26. Bedlack RS, Simel DL, Bosworth HS. myasthenia gravis score : Assessment of responsiveness and. *Neurology* 64, 1968–1970 (2005).
27. Ionita CM, Acsadi G. Management of Juvenile myasthenia gravis. *Pediatr. Neurol.* 48, 95–104 (2013).
28. Farrugia ME, Harle HD, Carmichael C, Burns TM. The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients. *Muscle and Nerve* 43, 329–334 (2011).
29. MGFA. Nutrition and myasthenia gravis. *Myasthenia Gravis Found. Am. Medical/Scientific Nurses Advis. Boards* 1, 13–14 (2010).
30. Godoy DA, de Mello, Masotti L, Napoli M. Pacientes miastênicos em crise: Uma melhora de conduta na unidade de terapia intensiva. *Arq. Neuropsiquiatr.* 71, 627–639 (2013).
31. Kulkantrakorn K, Jarungkiatkul W. Quality of life of myasthenia gravis patients. *J. Med. Assoc. Thail.* 93, 1167–1171 (2010).
32. Gilhus NE. Myasthenia gravis - Autoantibody characteristics and their implications for therapy. *Nat. Rev. Neurol.* 12, 259–268 (2016).
33. Sri-udomkajorn S, Panichai PL. Childhood myasthenia gravis: Clinical features and outcomes. *J Med. Assoc Thail.* 3, 152–157 (2011).
34. Naumes J, Hafer Macko. Exercise and Myasthenia Gravis: A Review of the Literature to Promote Safety, Engagement and Functioning. *Int.J. Neurorehabilitation* 3, 1-9 (2016).

35. Association of Western Pennsylvania. Stress and myasthenia gravis (MG). Myasthenia Gravis Found Am.2015; 21:1–4.
36. Zielonka T., Ryniewicz B, Szyluk B. How Accurate is Spirometry at Predicting Restrictive Pulmonary Impairment In Children With Myasthenia gravis (MG) is a relatively rare autoimmune disorder of peripheral nervous system.1,409–416 (2006).
37. Cavanaugh B. of the Literature. *Educ. Treat. Child.* 36, 111–137 (2013).
38. Peragallo, J. H. Pediatric Myasthenia Gravis. *Semin. Pediatr. Neurol.* 24, 116–121 (2017).
39. Vander Pluym. Clinical characteristics of pediatric myasthenia: A surveillance study. *Pediatrics* 132, (2013).
40. Soedjajadi, Keman. Kesehatan Perumahan Dan Lingkungan Pemukiman. Jurnal Kesehatan Lingkungan.2, 29 - 42 (2005).
41. Koneczny I, Herbst R. Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. *Cells* 8, 671 (2019).
42. Allen S. Management of myasthenia gravis. *Pharm. J.* 277, e476 (2006).
43. Malik YM, Dar JA, Almadani AA. Role of Myasthenia Gravis Auto-Antibodies as Predictor of Myasthenic Crisis and Clinical Parameters. *J. Neurol. Neurosci.* 10, 1–6 (2019).
44. Jayam TA, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: A review. *Autoimmune Dis.* 1, (2012).
45. Thanvi BR, Lo TC. Update on myasthenia gravis. *Postgrad. Med. J.* 80, 690–700 (2004).
46. Roper J, Fleming ME, Long B, Koyfman A. Myasthenia Gravis and Crisis: Evaluation and Management in the Emergency Department. *J. Emerg. Med.* 53, 843–853 (2017).
47. Mantegazza R, Bernasconi P, Cavalcante P. Myasthenia gravis: from autoantibodies to therapy. *Curr. Opin. Neurol.* 31, 517–525 (2018).
48. Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. *J. Neurol.* 263, 826–834 (2016).
49. Evoli A. Myasthenia gravis: New developments in research and treatment. *Curr. Opin. Neurol.* 30, 464–470 (2017).
50. Martínez Torre S, Gómez Molinero, Martínez Girón, R. Puesta al día en la miastenia gravis. *Semergen* 1–4 (2018)
51. Sanders D. Developing treatment guidelines for myasthenia gravis. *Ann. N. Y. Acad. Sci.* 1412, 95–101 (2018).